Recommended Topic Related To:

Cardura

"Dec. 18, 2012 -- People who can't get their high blood pressure down with drugs may be helped by a new procedure that deactivates overactive nerves in the kidneys, a small study shows.

The procedure is already available in Europe and "...

Cardura

SIDE EFFECTS

Benign Prostatic Hyperplasia (BPH)

The incidence of adverse events has been ascertained from worldwide clinical trials in 965 BPH patients. The incidence rates presented below (Table 3) are based on combined data from seven placebo-controlled trials involving once-daily administration of CARDURA in doses of 1–16 mg in hypertensives and 0.5–8 mg in normotensives. The adverse events when the incidence in the CARDURA group was at least 1% are summarized in Table 3. No significant difference in the incidence of adverse events compared to placebo was seen except for dizziness, fatigue, hypotension, edema, and dyspnea. Dizziness and dyspnea appeared to be dose-related.

TABLE 3 : ADVERSE REACTIONS DURING PLACEBO-CONTROLLED STUDIES BENIGN PROSTATIC HYPERPLASIA

Body System (N=665) (N=300)
BODY AS A WHOLE
  Back Pain 1.80% 2.00%
  Chest Pain 1.20% 0.70%
  Fatigue 8.0%* 1.70%
  Headache 9.90% 9.00%
  Influenza-like Symptoms 1.10% 1.00%
  Pain 2.00% 1.00%
CARDIOVASCULAR SYSTEM
  Hypotension 1.7%* 0.00%
  Palpitation 1.20% 0.30%
DIGESTIVE SYSTEM
  Abdominal Pain 2.40% 2.00%
  Diarrhea 2.30% 2.00%
  Dyspepsia 1.70% 1.70%
  Nausea 1.50% 0.70%
METABOLIC AND NUTRITIONAL DISORDERS
  Edema 2.7%* 0.70%
NERVOUS SYSTEM
  Dizziness† 15.6%* 9.00%
  Mouth Dry 1.40% 0.30%
  Somnolence 3.00% 1.00%
RESPIRATORY SYSTEM
  Dyspnea 2.6%* 0.30%
  Respiratory Disorder 1.10% 0.70%
SPECIAL SENSES
  Vision Abnormal 1.40% 0.70%
UROGENITAL SYSTEM
  Impotence 1.10% 1.00%
  Urinary Tract Infection 1.40% 2.30%
SKIN & APPENDAGES
  Sweating Increased 1.10% 1.00%
PSYCHIATRIC DISORDERS
  Anxiety 1.10% 0.30%
  Insomnia 1.20% 0.30%
*p ≤ 0.05 for treatment differences
†Includes vertigo

In these placebo-controlled studies of 665 CARDURA patients treated for a mean of 85 days, additional adverse reactions have been reported. These are less than 1% and not distinguishable from those that occurred in the placebo group. Adverse reactions with an incidence of less than 1% but of clinical interest are (CARDURA vs. placebo): Cardiovascular System: angina pectoris (0.6% vs. 0.7%), postural hypotension (0.3% vs. 0.3%), syncope (0.5% vs. 0.0%), tachycardia (0.9% vs. 0.0%); Urogenital System: dysuria (0.5% vs. 1.3%); and Psychiatric Disorders: libido decreased (0.8% vs. 0.3%). The safety profile in patients treated for up to three years was similar to that in the placebo-controlled studies.

The majority of adverse experiences with CARDURA were mild.

Hypertension

CARDURA has been administered to approximately 4000 hypertensive patients, of whom 1679 were included in the hypertension clinical development program. In that program, minor adverse effects were frequent, but led to discontinuation of treatment in only 7% of patients. In placebo-controlled studies, adverse effects occurred in 49% and 40% of patients in the doxazosin and placebo groups, respectively, and led to discontinuation in 2% of patients in each group. The major reasons for discontinuation were postural effects (2%), edema, malaise/fatigue, and some heart rate disturbance, each about 0.7%.

In controlled hypertension clinical trials directly comparing CARDURA to placebo, there was no significant difference in the incidence of side effects, except for dizziness (including postural), weight gain, somnolence, and fatigue/malaise. Postural effects and edema appeared to be dose-related. The prevalence rates presented below are based on combined data from placebo-controlled studies involving once-daily administration of doxazosin at doses ranging from 1–16 mg. Table 4 summarizes those adverse experiences (possibly/probably related) reported for patients in these hypertension studies where the prevalence rate in the doxazosin group was at least 0.5% or where the reaction is of particular interest.

TABLE 4 : ADVERSE REACTIONS DURING PLACEBO-CONTROLLED STUDIES

  HYPERTENSION DOXAZOSIN
(N=339)
PLACEBO
(N=336)
CARDIOVASCULAR SYSTEM
  Dizziness 19% 9%
  Vertigo 2% 1%
  Postural Hypotension 0.30% 0%
  Edema 4% 3%
  Palpitation 2% 3%
  Arrhythmia 1% 0%
  Hypotension 1% 0%
  Tachycardia 0.30% 1%
  Peripheral Ischemia 0.30% 0%
SKIN & APPENDAGES
  Rash 1% 1%
  Pruritus 1% 1%
MUSCULOSKELETAL SYSTEM
  Arthralgia/Arthritis 1% 0%
  Muscle Weakness 1% 0%
  Myalgia 1% 0%
CENTRAL & PERIPHERAL N.S.
  Headache 14% 16%
  Paresthesia 1% 1%
  Kinetic Disorders 1% 0%
  Ataxia 1% 0%
  Hypertonia 1% 0%
  Muscle Cramps 1% 0%
AUTONOMIC
  Mouth Dry 2% 2%
  Flushing 1% 0%
SPECIAL SENSES
  Vision Abnormal 2% 1%
  Conjunctivitis/Eye Pain 1% 1%
  Tinnitus 1% 0.30%
PSYCHIATRIC
  Somnolence 5% 1%
  Nervousness 2% 2%
  Depression 1% 1%
  Insomnia 1% 1%
  Sexual Dysfunction 2% 1%
CARDIOVASCULAR SYSTEM
  Dizziness 19% 9%
  Vertigo 2% 1%
  Postural Hypotension 0.30% 0%
  Edema 4% 3%
  Palpitation 2% 3%
  Arrhythmia 1% 0%
  Hypotension 1% 0%
  Tachycardia 0.30% 1%
  Peripheral Ischemia 0.30% 0%
SKIN & APPENDAGES  
  Rash 1% 1%
  Pruritus 1% 1%
MUSCULOSKELETAL SYSTEM
  Arthralgia/Arthritis 1% 0%
  Muscle Weakness 1% 0%
  Myalgia 1% 0%
CENTRAL & PERIPHERAL N.S.
  Headache 14% 16%
  Paresthesia 1% 1%
  Kinetic Disorders 1% 0%
  Ataxia 1% 0%
  Hypertonia 1% 0%
  Muscle Cramps 1% 0%
AUTONOMIC
  Mouth Dry 2% 2%
  Flushing 1% 0%
SPECIAL SENSES
  Vision Abnormal 2% 1%
  Conjunctivitis/Eye Pain 1% 1%
  Tinnitus 1% 0.30%
PSYCHIATRIC
  Somnolence 5% 1%
  Nervousness 2% 2%
  Depression 1% 1%
  Insomnia 1% 1%
  Sexual Dysfunction 2% 1%

Additional adverse reactions have been reported, but these are, in general, not distinguishable from symptoms that might have occurred in the absence of exposure to doxazosin. The following adverse reactions occurred with a frequency of between 0.5% and 1%: syncope, hypoesthesia, increased sweating, agitation, increased weight. The following additional adverse reactions were reported by < 0.5% of 3960 patients who received doxazosin in controlled or open, short-or long-term clinical studies, including international studies. Cardiovascular System: angina pectoris, myocardial infarction, cerebrovascular accident; Autonomic Nervous System: pallor; Metabolic: thirst, gout, hypokalemia; Hematopoietic: lymphadenopathy, purpura; Reproductive System: breast pain; Skin Disorders: alopecia, dry skin, eczema; Central Nervous System: paresis, tremor, twitching, confusion, migraine, impaired concentration; Psychiatric: paroniria, amnesia, emotional lability, abnormal thinking, depersonalization; Special Senses: parosmia, earache, taste perversion, photophobia, abnormal lacrimation; Gastrointestinal System: increased appetite, anorexia, fecal incontinence, gastroenteritis; Respiratory System: bronchospasm, sinusitis, coughing, pharyngitis; Urinary System: renal calculus; General Body System: hot flushes, back pain, infection, fever/rigors, decreased weight, influenza-like symptoms.

CARDURA has not been associated with any clinically significant changes in routine biochemical tests. No clinically relevant adverse effects were noted on serum potassium, serum glucose, uric acid, blood urea nitrogen, creatinine or liver function tests. CARDURA has been associated with decreases in white blood cell counts (see PRECAUTIONS, Leukopenia/Neutropenia).

In post-marketing experience, the following additional adverse reactions have been reported: Autonomic Nervous System: priapism; Central Nervous System: hypoesthesia; Endocrine System: gynecomastia; Gastrointestinal System: vomiting; General Body System: allergic reaction; Heart Rate/Rhythm: bradycardia; Hematopoietic: leukopenia, thrombocytopenia; Liver/Biliary System: hepatitis, hepatitis cholestatic; Respiratory System: bronchospasm aggravated; Skin Disorders: urticaria; Special Senses: Intraoperative Floppy Iris Syndrome (see PRECAUTIONS, Cataract Surgery); Urinary System: hematuria, micturition disorder, micturition frequency, nocturia.

Read the Cardura (doxazosin mesylate) Side Effects Center for a complete guide to possible side effects

DRUG INTERACTIONS

Most (98%) of plasma doxazosin is protein bound. In vitro data in human plasma indicate that CARDURA has no effect on protein binding of digoxin, warfarin, phenytoin, or indomethacin. There is no information on the effect of other highly plasma protein-bound drugs on doxazosin binding. CARDURA has been administered without any evidence of an adverse drug interaction to patients receiving thiazide diuretics, beta-blocking agents, and nonsteroidal anti-inflammatory drugs. In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of doxazosin on day 1 of a four-day regimen of oral cimetidine (400 mg twice daily) resulted in a 10% increase in mean AUC of doxazosin (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of doxazosin. The clinical significance of this increase in doxazosin AUC is unknown.

In clinical trials, CARDURA tablets have been administered to patients on a variety of concomitant medications; while no formal interaction studies have been conducted, no interactions were observed. CARDURA tablets have been used with the following drugs or drug classes: 1) analgesic/anti-inflammatory (e.g., acetaminophen, aspirin, codeine and codeine combinations, ibuprofen, indomethacin); 2) antibiotics (e.g., erythromycin, trimethoprim and sulfamethoxazole, amoxicillin); 3) antihistamines (e.g., chlorpheniramine); 4) cardiovascular agents (e.g., atenolol, hydrochlorothiazide, propranolol); 5) corticosteroids; 6) gastrointestinal agents (e.g., antacids); 7) hypoglycemics and endocrine drugs; 8) sedatives and tranquilizers (e.g., diazepam); 9) cold and flu remedies.

Concomitant administration of CARDURA with a phosphodiesterase-5 (PDE-5) inhibitor can result in additive blood pressure lowering effects and symptomatic hypotension (see DOSAGE AND ADMINISTRATION).

Cardiac Toxicity in Animals

An increased incidence of myocardial necrosis or fibrosis was displayed by Sprague-Dawley rats after 6 months of dietary administration at concentrations calculated to provide 80 mg doxazosin/kg/day, and after 12 months of dietary administration at concentrations calculated to provide 40 mg doxazosin/kg/day (AUC exposure in rats 8 times the human AUC exposure with a 12 mg/day therapeutic dose). Myocardial fibrosis was observed in both rats and mice treated in the same manner with 40 mg doxazosin/kg/day for 18 months (exposure 8 times human AUC exposure in rats and somewhat equivalent to human Cmax exposure in mice). No cardiotoxicity was observed at lower doses (up to 10 or 20 mg/kg/day, depending on the study) in either species. These lesions were not observed after 12 months of oral dosing in dogs at maximum doses of 20 mg/kg/day [maximum plasma concentrations (Cmax) in dogs 14 times the Cmax exposure in humans receiving a 12 mg/day therapeutic dose] and in Wistar rats at doses of 100 mg/kg/day (Cmax exposures 15 times human Cmax exposure with a 12 mg/day therapeutic dose). There is no evidence that similar lesions occur in humans.

Read the Cardura Drug Interactions Center for a complete guide to possible interactions

Last reviewed on RxList: 11/22/2013
This monograph has been modified to include the generic and brand name in many instances.

A A A

Cardura - User Reviews

Cardura User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Cardura sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Hypertension

Get tips on handling your hypertension.